Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Healthcare LLC

Tobias Marquardt

Alexandros Vakalopoulos

Johannes-Peter Stasch

Frank Wunder

Damian Brockschnieder

Volkhart Min-Jian Li

Markus Follmann

Lisa Dietz

Thomas Mondritzki

Alexander Straub

Gorden Redlich

Hanna Tinel

Henrik Teller

Matthias Beat Wittwer

Melissa Boultadakis Arapinis

Andrea Rotgeri

Ulrich Bothe

Philip Lienau

Gerhard Siemeister

Dieter Lang

Ulf Bömer

Adrian Tersteegen

Benjamin Bader

Niels Lindner

Marcus Koppitz

Thomas Ernst Müller

Dirk Kosemund

Antje Margret Wengner

Anne-Sophie Rebstock

Philipp Buchgraber

Ingo Hartung

Duy Nguyen

Volker Schulze

Hartmut Schirok

Markus Brechmann

Oliver Martin Fischer

Alexey Gromov

Naomi Barak

Matthias Busemann

Klaus Münter

Stefan Prechtl

Till Freudenberger

Maximillian Andreas Kullmann

Min Jian Volkhart Li

Christof Wegscheid-Gerlach

Simone Greven

Christoph Mahlert

Jan Tebbe

Stuart Ince

Christian Stegmann

Ernst Weber

Zhuozhi Wang

Mark Meininghaus

Dieter Moosmayer

Katrin Nowak-Reppel

Andreas Wilmen

Ilka Mathar

Bertolt Kreft

Lucas Hudson Hofmeister

Thomas Müller

Anke Mayer-bartschmid

Stuart Walsh

Marcel Geertz

Claudia Noack

Hannah Jörissen

Maximilian Andreas Kullmann

Daniela Fliegner

Isabella Gashaw

John Murphy

Ulf BÖMER

Philipp Lienau

Christof Wegscheidt-Gerlach

Katrin Nowak-reppel

The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).

Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Atrial natriuretic peptide engrafted antibodies

The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof

The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof

The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

Positive allosteric modulators of muscarinic M2 receptor

The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

Heteroaryl-substituted imidazo[1,2-A]pyridines and their use

The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof

The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-A]pyridines and their use

The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use

The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis. 

Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)

The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines

The present application relates to novel benzyl-1H-pyrazolo[3,4-b]pyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof

Growing community of inventors

Wuppertal, Germany

Tobias Marquardt